Tag
This article reviews how non-alpha IL2 receptor agonist pegenzileukin can counteract CD8 T-cell exhaustion, a key mechanism in CAR T-cell (CART19) therapy failure in relapsed/refractory large B-cell lymphoma, enhancing therapeutic efficacy
Emerging therapies have revolutionized first-line treatment in large B-cell lymphoma, but inconsistent trial designs and biomarker use create complexity. Harmonized strategies integrating biomarkers, pooled data, AI, and regulatory collabor
A comprehensive single-cell RNA sequencing study of large B cell lymphomas reveals five malignant B cell archetypes, with one subtype predictive of poor treatment response and survival, paving the way for precision therapy in LBCL.
Lisocabtagene maraleucel demonstrates durable five-year survival and potential cure in relapsed/refractory large B-cell lymphoma, with manageable long-term safety, based on data from the TRANSCEND NHL 001 trial and its long-term follow-up.
This study demonstrates that detection of circulating tumor DNA (ctDNA) after treatment in large B-cell lymphoma predicts progression-free survival, highlighting the clinical utility of a rapid immunoglobulin rearrangement-targeted assay fo
This review synthesizes real-world data from the DESCAR-T registry on CAR T-cell therapy response kinetics in large B-cell lymphoma, highlighting the prognostic impact of early response patterns and factors influencing conversion from parti
This study compares outcomes of CAR T-cell therapy and allogeneic stem cell transplantation based on IPI risk factors in relapsed/refractory LBCL, highlighting favorable survival with CAR T-cell therapy in low-risk patients but advocating a
A retrospective study of 584 Australian lymphoma patients shows no significant link between CAR T-cell infusion timing and treatment outcomes, suggesting chronobiology may not influence results in large B-cell lymphoma therapy.
In the randomized phase III SUNMO trial, mosunetuzumab plus polatuzumab vedotin significantly improved response rates and progression‑free survival versus R‑GemOx in transplant‑ineligible relapsed/refractory large B‑cell lymphoma, with low
Detection of circulating tumor DNA (ctDNA) provides a highly prognostic method for assessing remission in large B-cell lymphoma, outperforming conventional imaging and promising improved patient outcomes.
The 3-year follow-up of the phase III TRANSFORM study demonstrates that lisocabtagene maraleucel (liso-cel) provides superior durable efficacy and a favorable safety profile compared with standard of care in second-line relapsed/refractory
Three-year follow-up from the phase III TRANSFORM trial confirms lisocabtagene maraleucel (liso-cel) significantly improves event-free survival and response durability over standard of care in second-line relapsed/refractory large B-cell ly
This phase II trial shows that combining glofitamab with R-CHOP or Pola-R-CHP is safe and effective as first-line treatment in younger patients with high-risk large B-cell lymphoma, achieving high durable response rates and manageable side
